Brief: Marker Therapeutics Reports Q1 2022 Operating And Financial Results
13/05/2022 12:37
May 13 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS REPORTS Q1 2022 OPERATING AND
FINANCIAL
RESULTS
* MARKER THERAPEUTICS INC - PLANS TO FILE INDS IN LYMPHOMA
AND
PANCREATIC CANCER BY YEAR END, WITH CLINICAL TRIALS TO BE
INITIATED IN 2023
* MARKER THERAPEUTICS INC QTRLY LOSS PER SHARE $0.12
Source text for Eikon: ID:nGNX1tpvkn
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79